Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]

View source ↗

Summary

Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including essential thrombocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasms
• Polycythemia Vera
• Venous Thromboembolism

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Status: COMPLETED